FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年3月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: EPS創健科技集團有限公司 (於開曼群島註冊成立之有限公司) 呈交日期: 2026年4月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 不適用 | | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 03860 | 說明 | | | | | | | | | 法定/註冊股份數目 | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | 1,000,000,000 | HKD | | 0.01 HKD | | 10,000,000 | | 增加 / 減少 (-) | | | 0 | | HKD | | 0 | | 本月底結存 | | 1,000,000,000 | HKD | | 0.01 HKD | | 10,000,000 | 本月底法定/註冊股本總額： HK ...

香港交易及結算所有限公司以及香港聯合交易所有限公司對本公告的內容概不負責，對 其準確性或完整性亦不發表任何聲明，並明確表示，概不會就因本公告全部或任何部分 內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 3860 由於需要額外時間落實通函，現預期寄發通函的日期將延遲至二零二六年四月二十日或 之前。 由於進一步延遲寄發通函，於二零二六年三月二十七日，賣方與本公司同意將達成協議 條件的最後日期及時間（「最後截止日期」）延長至二零二六年五月三十日中午十二時正（或 賣方與本公司或會進一步協定的其他日期及時間）。 - 1 - 除上述披露者外，協議的所有其他條款及條件維持不變，仍具十足效力及有效。 承董事會命 EPS創健科技集團有限公司 進一步延遲寄發通函 及 延長最後截止日期 內容有關須予披露及關連交易 茲提述EPS創健科技集團有限公司（「本公司」）日期為二零二六年二月十二日的公告（「該公 告」），內容有關收購事項及其項下擬進行的交易；及本公司日期為二零二六年三月十日 的公告（「延遲公告」），內容有關延遲寄發通函。除另有說明外，本公告所用詞彙與該公 告及延遲公告所界定者具有相同涵義。 誠如延遲公告所披露，載有 ...

香港交易及結算所有限公司以及香港聯合交易所有限公司對本公告的內容概不負責，對 其準確性或完整性亦不發表任何聲明，並明確表示，概不會就因本公告全部或任何部分 內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 茲提述EPS創健科技集團有限公司（「本公司」）日期為二零二六年二月十二日的公告（「該公 告」），內容有關收購事項及其項下擬進行的交易。除另有說明外，本公告所用詞彙與該 公告所界定者具有相同涵義。 誠如該公告所披露，一份載有（其中包括）(i)收購事項的進一步詳情；(ii)獨立董事委員會 函件；(iii)獨立財務顧問函件；(iv)銷售股份的估值報告；及(v)股東特別大會通告之通函 （「通函」），預期於二零二六年三月十日或之前寄發予股東。 由於本公司需要額外時間編撰及落實供載入通函之若干資料，現預期寄發通函的日期將 延遲至二零二六年三月二十七日或之前。 承董事會命 EPS創健科技集團有限公司 3860 延遲寄發通函 於本公告日期，執行董事為鷲北健一郎先生、宮野積先生、嗚海尚一先生、趙俊德先 生、杜垚女士及梁非先生；非執行董事為植松高宏先生及嚴平先生；及獨立非執行董事 為陳卓豪先生、蔡冠明先生、齋藤宏暢先生 ...

致：香港交易及結算所有限公司 公司名稱: EPS創健科技集團有限公司 (於開曼群島註冊成立之有限公司) 呈交日期: 2026年3月2日 FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 FF301 II. 已發行股份及/或庫存股份變動及足夠公眾持股量的確認 1. 股份分類 普通股 股份類別 不適用 於香港聯交所上市 (註1) 是 證券代號 (如上市) 03860 說明 已發行股份（不包括庫存股份）數目 庫存股份數目 已發行股份總數 上月底結存 522,177,419 0 522,177,419 增加 / 減少 (-) 0 0 本月底結存 522,177,419 0 522,177,419 足夠公眾持股量的確認(註4) | 根據《主板上市規則》第13.32D(1)條或第19A.28D(1)條 / 《GEM上市規則》第17.37D(1)條或第25.21D(1)條，我們在此確認，就上述所列股份類別而言，截至本月底: | | --- | | ✔ 已符合適用的公眾持股量要求（見下方） | | 未符合適用的公眾持股量要求（見下方） ...

Group 1 - The company has agreed to acquire 1,623 ordinary shares of China Gene, representing 16.23% of its issued share capital, for a total cash consideration of HKD 43 million [1] - China Gene's main subsidiary, Huaxin, focuses on the research, production, and sales of biopharmaceutical products, particularly in gynecology and gene cell therapy [1] - The acquisition is seen as a strategic investment that will allow the company to expand its market presence in the healthcare and biopharmaceutical sectors in China, which are expected to grow significantly [2][3] Group 2 - The board believes that the acquisition will create potential long-term value and enhance the company's revenue through collaboration in the distribution of China Gene's biopharmaceutical products [2] - China Gene plans to adopt a dividend policy, aiming to distribute at least one-third of its after-tax profits after necessary provisions, which is expected to provide positive financial returns for the company [3] - The company currently has no plans or intentions for further acquisitions of China Gene's shares in the foreseeable future [4]

Core Viewpoint - The company EPS Creation Technology (03860) has agreed to acquire 1,623 shares of China Gene, representing 16.23% of its issued share capital, for a total cash consideration of HKD 43 million, which will be recognized as an investment in an associate in the consolidated financial statements of the group [1] Group 1: Acquisition Details - The acquisition agreement is set to be completed on February 12, 2026, with the total cash consideration being HKD 43 million [1] - Following the completion, the investment in China Gene will be accounted for as an investment in an associate [1] Group 2: Business Synergy and Strategy - The acquisition aligns with the company's existing healthcare product trading, medical device leasing, and CRO services, providing an excellent opportunity to participate in the operations of China Gene, which is experiencing strong growth in the favorable Chinese healthcare and biopharmaceutical market [2] - The company can leverage its extensive sales network in healthcare product trading to assist in the distribution of China Gene's listed biopharmaceutical products, potentially increasing revenue [2] - The integration of the value chain in the healthcare and biopharmaceutical ecosystem is expected to create synergies between the company's HCP and CRO businesses [2] Group 3: Financial Expectations - China Gene plans to adopt a dividend policy, aiming to distribute at least one-third of its after-tax profits after necessary provisions for taxes, loan repayments, and working capital needs [3] - The board anticipates that the investment in China Gene will yield positive financial returns and provide good business opportunities for future development, given its past profitability and dividend policy [3] - The acquisition is viewed as a strategic investment that will enhance the company's market participation in the Chinese healthcare and biopharmaceutical sectors, contributing positively to overall financial performance and long-term growth [3] Group 4: Future Acquisition Plans - The company currently has no plans or intentions for further acquisitions of equity in China Gene in the foreseeable future [4]

香港交易及結算所有限公司以及香港聯合交易所有限公司對本公告的內容概不負責，對 其準確性或完整性亦不發表任何聲明，並明確表示，概不會就因本公告全部或任何部分 內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 3860 須予披露及關連交易 內容有關 收購中國基因工程有限公司16.23%已發行股份 協議 標的事項 於二零二六年二月十二日（交易時段結束後），本公司（作為買方）與賣方（作為賣方）訂 立協議，據此，本公司有條件同意收購而賣方有條件同意出售銷售股份，總現金代價 為43,000,000港元。緊隨完成後，本集團於中國基因的投資將於本集團的綜合財務報 表內確認為於聯營公司的投資。 上市規則涵義 由於收購事項的一項或多項適用百分比率超過5%但所有相關百分比率均低於25%，故 而根據上市規則第14章收購事項構成本公司的須予披露交易，並須遵守上市規則第14 章項下的通知及公告規定。 於本公告日期，賣方由非執行董事嚴平先生及執行董事趙俊德先生實益擁有。因此， 根據上市規則，賣方為本公司的關連人士，且協議項下擬進行的交易構成本公司的關 連交易。由於收購事項的一項或多項適用百分比率超過5%，且收購事項的總代價超過 1 ...

Core Viewpoint - The company has entered into a memorandum of understanding to acquire a 16.23% stake in China Gene Engineering Company for approximately HKD 40 million to HKD 45 million, which is seen as a strategic investment to enhance its participation in the healthcare sector and create long-term value [1] Group 1: Acquisition Details - The acquisition involves China Gene Engineering Company, which is registered in Hong Kong and holds approximately 67.68% of Shanghai Huaxin Biological High-tech Co., Ltd [1] - The total consideration for the acquisition is estimated to be between HKD 40 million and HKD 45 million [1] Group 2: Business Synergy - China Gene Group is primarily engaged in the internal research and development, manufacturing, and sales of biopharmaceutical products in China [1] - The acquisition aligns with the company's existing businesses in healthcare product trading, medical device leasing, and providing professional contract research organization (CRO) services [1] Group 3: Strategic Importance - The board views the acquisition as an excellent opportunity to increase the company's involvement in the operations of China Gene Group [1] - This strategic investment is expected to generate potential long-term value and facilitate business development in the promising healthcare industry [1]

Core Viewpoint - The company EPS Creative Technology (03860) has signed a memorandum of understanding to acquire a 16.23% stake in China Gene Engineering Co., Ltd. from Hongshida Medical Co., Ltd. for approximately HKD 40 million to HKD 45 million, which is seen as a strategic investment to enhance its involvement in the healthcare sector and create long-term value [1][1][1] Group 1 - The acquisition involves China Gene Engineering, a Hong Kong-registered company that holds about 67.68% of Shanghai Huaxin Bio-Technology Co., Ltd. [1] - The transaction is expected to complement the company's existing businesses in healthcare product trading, medical device leasing, and providing professional contract research organization (CRO) services [1][1] - Upon completion, the investment in China Gene will be recognized as an investment in an associate company in the group's consolidated financial statements [1]

Core Viewpoint - The company, EPS Creation Technology (03860.HK), has signed a memorandum of understanding to acquire a 16.23% stake in China Gene Engineering Co., Ltd, which is seen as a strategic investment to enhance its involvement in the biopharmaceutical sector and create long-term value [1] Group 1: Acquisition Details - The acquisition involves China Gene Engineering Co., Ltd, a company registered in Hong Kong, which holds approximately 67.68% of Shanghai Huaxin Biological High-Tech Co., Ltd [1] - The acquisition is expected to be recognized as an investment in an associate company in the consolidated financial statements of the group upon completion [1] Group 2: Strategic Importance - The board believes that this acquisition presents an excellent opportunity for the group to expand its operational involvement with China Gene Group [1] - The investment aligns with the group's existing business in healthcare product trading, medical device leasing, and providing professional contract research organization (CRO) services, thereby complementing its current operations [1]